Association between increased serum interleukin-6 levels and sustained attention deficits in patients with major depressive disorder

Abstract Background The pathophysiology of cognitive impairment in patients with the major depressive disorder (MDD) may involve neuroinflammation mediated by cytokines. Objective The aim of this study was to examine the serum interleukin-6 (IL-6) levels, sustained attention, and their association in patients with MDD. Methods Thirty patients with MDD and 30 healthy controls were enrolled in this case-control study. Sustained attention was measured using the Rapid Visual Information Processing (RVP) task in the Cambridge Neuropsychological Tests Automated Battery. The serum IL-6 levels of all subjects were assessed by sandwich enzyme-linked immunosorbent assays. Results There were significant differences in the log10RVP total hits, log10RVP total misses, and log10RVP mean latency between patients with MDD and healthy controls (F = 6.04, p = 0.017; F = 19.77, p < 0.0001; F = 14.42, p < 0.0001, respectively). The serum levels of Log10IL-6 were significantly higher in patients with MDD than in healthy controls (F = 192.27, p < 0.0001). The log10IL-6 levels were also positively correlated with the log10RVP mean latency in patients with MDD (r = 0.45, p = 0.013). A further stepwise multivariate regression analysis indicated that the log10IL-6 levels were significantly associated with the log10RVP mean latency in patients with MDD (β = 0.31, t = 2.41, p = 0.025). Conclusions Our data suggested that increased IL-6 levels were associated with the psychopathology of MDD, and that abnormal IL-6 levels were implicated in the impairment of sustained attention in patients with MDD.

[1]  Y. Zang,et al.  The Inter-Regional Connectivity Within the Default Mode Network During the Attentional Processes of Internal Focus and External Focus: An fMRI Study of Continuous Finger Force Feedback , 2019, Front. Psychol..

[2]  J. Landowski,et al.  Peripheral blood lymphocyte subpopulations in patients with bipolar disorder type II , 2019, Scientific Reports.

[3]  Mohammad Fahim Kadir,et al.  Evaluation of Serum Interleukin-6 and C-reactive Protein Levels in Drug-naïve Major Depressive Disorder Patients , 2019, Cureus.

[4]  G. Lewis,et al.  Childhood inflammatory markers and intelligence as predictors of subsequent persistent depressive symptoms: a longitudinal cohort study , 2017, Psychological Medicine.

[5]  J. Wu,et al.  Elevated triglyceride levels are associated with cognitive impairments among patients with major depressive disorder. , 2017, Comprehensive psychiatry.

[6]  D. Goldsmith,et al.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.

[7]  Zhi-guo Wu,et al.  Identification of IL6 as a susceptibility gene for major depressive disorder , 2016, Scientific Reports.

[8]  F. Wright,et al.  Gene expression in major depressive disorder. , 2016, Molecular psychiatry.

[9]  F. Wright,et al.  Gene expression in major depressive disorder , 2016, Molecular Psychiatry.

[10]  R. Fonseca,et al.  Executive function impairments in depression and bipolar disorder: association with functional impairment and quality of life. , 2016, Journal of affective disorders.

[11]  W. Deng,et al.  Gray matter volume abnormalities were associated with sustained attention in unmedicated major depression. , 2015, Comprehensive psychiatry.

[12]  M. Maes,et al.  High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance , 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[13]  I. Goodyer.  Genes, environments and depressions in young people , 2015, Archives of Disease in Childhood.

[14]  Alan A. Wilson,et al.  Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. , 2015, JAMA psychiatry.

[15]  C. Hammen,et al.  Effects of Chronic Interpersonal Stress Exposure on Depressive Symptoms are Moderated by Genetic Variation at IL6 and IL1β in Youth , 2015, Brain, Behavior, and Immunity.

[16]  Kichun Nam,et al.  Impact of lingual gyrus volume on antidepressant response and neurocognitive functions in Major Depressive Disorder: a voxel-based morphometry study. , 2014, Journal of affective disorders.

[17]  K. Blennow,et al.  Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample , 2014, Brain, Behavior, and Immunity.

[18]  B. Misiak,et al.  Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation , 2014, European Archives of Psychiatry and Clinical Neuroscience.

[19]  Min Zhao,et al.  Reliability and validity of the Chinese version of the Patient Health Questionnaire (PHQ-9) in the general population. , 2014, General hospital psychiatry.

[20]  E. Rimm,et al.  C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression. , 2014, Journal of affective disorders.

[21]  O. Andreassen,et al.  The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery , 2014, Psychoneuroendocrinology.

[22]  N. Barnes,et al.  Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.

[23]  Y. D. Reijmer,et al.  Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population – the Hoorn Study , 2014, Psychoneuroendocrinology.

[24]  J. Roiser,et al.  Cognitive impairment in depression: a systematic review and meta-analysis , 2013, Psychological Medicine.

[25]  E. Maylor,et al.  Intracellular cytokine production and cognition in healthy older adults , 2013, Psychoneuroendocrinology.

[26]  M. Gratacós,et al.  Serotonin and interleukin-6: The role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms , 2013, Psychoneuroendocrinology.

[27]  F. Lotrich,et al.  Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications , 2013, Neuroscience.

[28]  R. Murray,et al.  Serum and gene expression profile of cytokines in first-episode psychosis , 2013, Brain, Behavior, and Immunity.

[29]  N. Sattar,et al.  Circulating interleukin‐6 concentration and cognitive decline in old age: the PROSPER study , 2013, Journal of internal medicine.

[30]  D. Kinney,et al.  Depression as an evolutionary strategy for defense against infection , 2013, Brain, Behavior, and Immunity.

[31]  N. Arsenijević,et al.  Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. , 2012, Journal of psychiatric research.

[32]  R. Lee,et al.  A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. , 2012, Journal of affective disorders.

[33]  R. Ho,et al.  Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. , 2012, Journal of Affective Disorders.

[34]  A. Baker,et al.  Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis , 2012, Psychological Medicine.

[35]  Wu Hong,et al.  Blood-Based Gene Expression Profiles Models for Classification of Subsyndromal Symptomatic Depression and Major Depressive Disorder , 2012, PloS one.

[36]  B. Sahakian,et al.  Neurocognitive impairment in adolescent major depressive disorder: state vs. trait illness markers. , 2011, Journal of affective disorders.

[37]  B. Penninx,et al.  Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. , 2011, The American journal of psychiatry.

[38]  L. Hansson,et al.  Cytokines and memory across the mature life span of women. , 2011, Scandinavian journal of psychology.

[39]  Andrew H. Miller,et al.  Immune system to brain signaling: neuropsychopharmacological implications. , 2011, Pharmacology & therapeutics.

[40]  Y. Levkovitz,et al.  The effect of age on frontal lobe related cognitive functions of unmedicated depressed patients. , 2011, Journal of affective disorders.

[41]  C. Jonker,et al.  Homocysteine and inflammation: Predictors of cognitive decline in older persons? , 2010, Neurobiology of Aging.

[42]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[43]  Jen-Chuen Hsieh,et al.  Structural and cognitive deficits in remitting and non-remitting recurrent depression: A voxel-based morphometric study , 2010, NeuroImage.

[44]  R. Marioni,et al.  Association Between Raised Inflammatory Markers and Cognitive Decline in Elderly People With Type 2 Diabetes , 2009, Diabetes.

[45]  Klaus P. Ebmeier,et al.  A meta-analysis of depression severity and cognitive function. , 2009, Journal of affective disorders.

[46]  T. Kamarck,et al.  A prospective evaluation of the directionality of the depression–inflammation relationship , 2009, Brain, Behavior, and Immunity.

[47]  Qichang Shi,et al.  Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey , 2009, The Lancet.

[48]  S. Bandinelli,et al.  Interleukin-1 Receptor Antagonist and Incident Depressive Symptoms Over 6 Years in Older Persons: The InCHIANTI Study , 2009, Biological Psychiatry.

[49]  Charles L. Raison,et al.  Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.

[50]  J. Suls,et al.  Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.

[51]  Donald L Rowe,et al.  Fronto‐temporal alterations within the first 200 ms during an attentional task distinguish major depression, non‐clinical participants with depressed mood and healthy controls: A potential biomarker? , 2009, Human brain mapping.

[52]  M. Marmot,et al.  Inflammatory markers and cognitive function in middle-aged adults: The Whitehall II study , 2008, Psychoneuroendocrinology.

[53]  M G Marmot,et al.  Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study , 2008, Psychological Medicine.

[54]  A. Caspi,et al.  Elevated inflammation levels in depressed adults with a history of childhood maltreatment. , 2008, Archives of general psychiatry.

[55]  R. Stewart,et al.  Markers of inflammation and cognitive decline in an African‐Caribbean population , 2007, International journal of geriatric psychiatry.

[56]  Derek T. Y. Mann,et al.  Perceptual-cognitive expertise in sport: a meta-analysis. , 2007, Journal of sport & exercise psychology.

[57]  R. Westendorp,et al.  Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age , 2007, Experimental Gerontology.

[58]  N. Börger,et al.  Sustained Attention in Major Unipolar Depression , 2007, Perceptual and motor skills.

[59]  I. Deary,et al.  Cognitive Decline and Markers of Inflammation and Hemostasis: The Edinburgh Artery Study , 2007, Journal of the American Geriatrics Society.

[60]  J. Flory,et al.  Interleukin-6 Covaries Inversely With Cognitive Performance Among Middle-Aged Community Volunteers , 2006, Psychosomatic medicine.

[61]  Johannes Pohl,et al.  Attention and executive functions in remitted major depression patients. , 2005, Journal of affective disorders.

[62]  M. Skolnick,et al.  Genome‐wide linkage analyses of extended Utah pedigrees identifies loci that influence recurrent, early‐onset major depression and anxiety disorders , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[63]  Kristopher J Preacher,et al.  Chronic stress and age-related increases in the proinflammatory cytokine IL-6 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[64]  M. Korzon,et al.  Serum interleukin 6 and interleukin 12 levels in children with chronic hepatitis HBV treated with interferon alpha. , 2003, Annals of hepatology.

[65]  Richard J. Porter,et al.  Neurocognitive impairment in drug-free patients with major depressive disorder , 2003, British Journal of Psychiatry.

[66]  C. Nemeroff,et al.  Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.

[67]  H. Link,et al.  Enzyme-Linked Immunospot Assays Provide a Sensitive Tool for Detection of Cytokine Secretion by Monocytes , 2001, Clinical Diagnostic Laboratory Immunology.

[68]  B. Hagerty,et al.  Changes in directed attention and short-term memory in depression. , 2000, Journal of psychiatric research.

[69]  K. Akiyama.  Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration , 1999, Schizophrenia Research.

[70]  N. Rothwell,et al.  Cerebral Interleukin-6 is Neuroprotective during Permanent Focal Cerebral Ischemia in the Rat , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[71]  R G Robinson,et al.  Cognitive impairment in the euthymic phase of chronic unipolar depression. , 1997, The Journal of nervous and mental disease.

[72]  C. Frith,et al.  A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory , 1996, Neuropsychologia.

[73]  R. Zinkernagel,et al.  Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.

[74]  B. Rabin,et al.  Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness , 1994, Psychiatry Research.

[75]  A M Owen,et al.  Computerized assessment in neuropsychiatry using CANTAB: discussion paper. , 1992, Journal of the Royal Society of Medicine.

[76]  L. Saugstad,et al.  In defence of international classification , 1985, Psychological Medicine.

[77]  Muriel D. Lezak,et al.  The Problem of Assessing Executive Functions , 1982 .

[78]  Lucas Wexler.  Principles Of Behavioral Neurology , 2016 .

[79]  D. F. Drake,et al.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. , 2013, JAMA psychiatry.

[80]  R. Grassi‐Oliveira,et al.  Interleukin-6 and verbal memory in recurrent major depressive disorder. , 2011, Neuro endocrinology letters.

[81]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[82]  R. Sacco,et al.  Interleukin-6 is associated with cognitive function: the Northern Manhattan Study. , 2006, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.